Skip to main content

Table 9 One-way sensitivity analysis results for genotype 1 comparing peginterferon-alfa-2a to peginterferon-alfa-2b

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Parameter

Lower parameter value

Higher parameter value

Result

Cost difference

LY difference

QALY difference

Cost difference

LY difference

QALY difference

Utility values1

-$Brz 8001

0,16

0,54

-$Brz 8001

0,16

0,27

Dominant

Medical costs1

-$Brz 7610

0,16

0,41

-$Brz 8392

0,16

0,41

Dominant

State-transition probabilities1

-$Brz 7851

0,12

0,37

-$Brz 8105

0,20

0,44

Dominant

Peginterferon-alfa-2a acquisition cost1

-$Brz 9938

0,16

0,41

-$Brz 6063

0,16

0,41

Dominant

Peginterferon-alfa-2b acquisition cost1

-$Brz 5254

0,16

0,41

-$Brz 10747

0,16

0,41

Dominant

Patient weight2

-$Brz 2769

0,16

0,41

-$Brz 13232

0,16

0,41

Dominant

SVR3

-$Brz 7902

0,16

0,39

-$Brz 8099

0,17

0,42

Dominant

Starting age4

-$Brz 8181

0,20

0,45

-$Brz 7788

0,14

0,37

Dominant

  1. Notes: 1Parameters were varied over the range of ±15%; 2Parameter was varied from 50 to 90 kg; 3Parameter was varied according to lower and upper limit values obtained from meta-analysis; 4Parameter was varied from 40 to 50 years old.